{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:23:22Z","timestamp":1785529402448,"version":"3.56.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,5,2]],"date-time":"2015-05-02T00:00:00Z","timestamp":1430524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s10157-015-1117-z","type":"journal-article","created":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T01:28:01Z","timestamp":1430443681000},"page":"543-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities"],"prefix":"10.1007","volume":"19","author":[{"given":"Takashi","family":"Hirukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,5,2]]},"reference":[{"issue":"Suppl. 113","key":"1117_CR1","first-page":"S1","volume":"76","author":"KDIGO Clinical Practice Guideline for the Diagnosis","year":"2009","unstructured":"KDIGO Clinical Practice Guideline for the Diagnosis. Evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl. 113):S1\u2013130.","journal-title":"Kidney Int"},{"key":"1117_CR2","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","volume":"17","author":"M Fukagwa","year":"2013","unstructured":"Fukagwa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorders. Ther Apher Dial. 2013;17:247\u201388.","journal-title":"Ther Apher Dial."},{"key":"1117_CR3","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003\u20138.","journal-title":"J Clin Invest."},{"key":"1117_CR4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370\u20138.","journal-title":"Kidney Int"},{"key":"1117_CR5","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1073\/pnas.1221255110","volume":"110","author":"ZC Ryan","year":"2013","unstructured":"Ryan ZC, Ketha H, McNulty MS, et al. Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA. 2013;110:6199\u2013204.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1117_CR6","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2215\/CJN.06550810","volume":"6","author":"D Cejka","year":"2011","unstructured":"Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6:877\u201382.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1117_CR7","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","volume":"25","author":"X Li","year":"2010","unstructured":"Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25:2647\u201356.","journal-title":"J Bone Miner Res"},{"key":"1117_CR8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","volume":"26","author":"D Padhi","year":"2011","unstructured":"Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19\u201326.","journal-title":"J Bone Miner Res"},{"key":"1117_CR9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/(SICI)1098-2388(199703\/04)13:2<78::AID-SSU3>3.0.CO;2-Z","volume":"13","author":"Y Tominaga","year":"1997","unstructured":"Tominaga Y, Tanaka Y, Sato K, et al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:78\u201386.","journal-title":"Semin Surg Oncol"},{"key":"1117_CR10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000110875","volume":"28","author":"SM Sprague","year":"2008","unstructured":"Sprague SM, Belozeroff V, Danese MD, et al. Abnormal bone and mineral metabolism in kidney transplant patients\u2014a review. Am J Nephrol. 2008;28:246\u201353.","journal-title":"Am J Nephrol"},{"key":"1117_CR11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1399-0012.2010.01287.x","volume":"25","author":"JB Copley","year":"2011","unstructured":"Copley JB, Wuthrich RP. Therapeutic management of post kidney transplant hyperparathyroidism. Clin Transplant. 2011;25:24\u201339.","journal-title":"Clin Transplant"},{"key":"1117_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/00365599409180465","volume":"28","author":"HH Saha","year":"1994","unstructured":"Saha HH, Salmela KT, Ahonen PJ, et al. Sequential changes in vitamin D and calcium metabolism after successful renal transplantation. Scand J Urol Nephrol. 1994;28:21\u20137.","journal-title":"Scand J Urol Nephrol"},{"key":"1117_CR13","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/ndt\/17.7.1318","volume":"17","author":"JP Casez","year":"2002","unstructured":"Casez JP, Lippuner K, Horber FF, et al. Changes in bone mineral density over 18\u00a0months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant. 2002;17:1318\u201326.","journal-title":"Nephrol Dial Transplant"},{"key":"1117_CR14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ncpneph0124","volume":"2","author":"J Amanzadeh","year":"2006","unstructured":"Amanzadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Protect Nephrol. 2006;2:136\u201348.","journal-title":"Nat Clin Protect Nephrol"},{"key":"1117_CR15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1681\/ASN.V132551","volume":"13","author":"A Torres","year":"2002","unstructured":"Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol. 2002;13:551\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"1117_CR16","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.ki.5001788","volume":"70","author":"I Bhan","year":"2006","unstructured":"Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: tertiary \u2018hyper-phosphatonism\u2019? Kidney Int. 2006;70:1486\u201396.","journal-title":"Kidney Int"},{"key":"1117_CR17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1744-9987.2011.00932.x","volume":"15","author":"Hiroo Kawarazaki","year":"2011","unstructured":"Kawarazaki Hiroo, Shibagaki Yugo, Fukumoto Seiji, et al. Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study. Ther Apher Dial. 2011;15:481\u20137.","journal-title":"Ther Apher Dial."},{"key":"1117_CR18","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/ndt\/gfh128","volume":"19","author":"P Evenepoel","year":"2004","unstructured":"Evenepoel P, Claes K, Kuypers D, et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19:1281\u20137.","journal-title":"Nephrol Dial Transplant."},{"key":"1117_CR19","first-page":"67","volume":"52","author":"T Cundy","year":"1983","unstructured":"Cundy T, Kanis JA, Heynen G, et al. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med. 1983;52:67.","journal-title":"Q J Med."},{"key":"1117_CR20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s00198-004-1653-y","volume":"16","author":"SD Roe","year":"2005","unstructured":"Roe SD, Porter CJ, Godber IM, et al. Reduced bone mineral density in male renal transplant recipients: evidence for persisting hyperparathyroidism. Osteoporos Int. 2005;16:142.","journal-title":"Osteoporos Int"},{"key":"1117_CR21","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/sj.ki.5001600","volume":"70","author":"Y Iwasaki","year":"2006","unstructured":"Iwasaki Y, Yamato H, Nii-Kono T, et al. Insufficiency of PTH action of bone in uremia. Kidney Int. 2006;70:S34.","journal-title":"Kidney Int"},{"key":"1117_CR22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1600-6143.2007.01753.x","volume":"7","author":"P Evenepoel","year":"2007","unstructured":"Evenepoel P, Naesens M, Claes K, et al. Tertiary \u2018hyperphosphatoninism\u2019 accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant. 2007;7:1193\u20132000.","journal-title":"Am J Transplant"},{"key":"1117_CR23","doi-asserted-by":"crossref","first-page":"C21","DOI":"10.1159\/000066640","volume":"93","author":"RG Sevaux de","year":"2003","unstructured":"de Sevaux RG, Hoitsma AJ, van Hoof HJ, et al. Abnormal vitamin D metabolism and loss of bone mass after renal transplantation. Nephron Clin Pract. 2003;93:C21\u20138.","journal-title":"Nephron Clin Pract."},{"key":"1117_CR24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/BF00175756","volume":"21","author":"B Bagni","year":"1994","unstructured":"Bagni B, Gilli P, Cavallini A, et al. Continuing loss of vertebral mineral density in renal transplant recipients. Eur J Nucl Med. 1994;21:108\u201312.","journal-title":"Eur J Nucl Med"},{"key":"1117_CR25","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/sj.ki.5001549","volume":"70","author":"M Taniguchi","year":"2006","unstructured":"Taniguchi M, Tokumoto M, Matsuo D, et al. Persistent hyperparathyroidism in renal allograft recipients:vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006;70:363\u201370.","journal-title":"Kidney Int."},{"key":"1117_CR26","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1038\/ki.2010.283","volume":"78","author":"H Komaba","year":"2010","unstructured":"Komaba H, Koizumi M, Fukagawa M. Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future? Kidney Int. 2010;78:953\u20135.","journal-title":"Kidney Int"},{"key":"1117_CR27","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/1744-9987.12018","volume":"17","author":"M Nakamura","year":"2013","unstructured":"Nakamura M, Tanaka K, Marui Y, et al. Clinicopathological analysis of persistent hypercalcemia and hyperparathyroidism after kidney transplantation in long-term dialysis patients. Ther Apher Dial. 2013;17:551\u20136.","journal-title":"Ther Apher Dial."},{"key":"1117_CR28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.semnephrol.2012.12.019","volume":"33","author":"P Evenepoel","year":"2013","unstructured":"Evenepoel P. Recovery versus persistence of disordered mineral metabolism in kidney transplant recipients. Semin Nephrol. 2013;33:191\u2013203.","journal-title":"Semin Nephrol"},{"key":"1117_CR29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","volume":"2","author":"H Takayanagi","year":"2002","unstructured":"Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1(NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;2:889\u2013901.","journal-title":"Dev Cell."},{"key":"1117_CR30","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.bone.2007.02.017","volume":"40","author":"H Yeo","year":"2007","unstructured":"Yeo H, Beck LH, McDonald JM, et al. Cyclosporin a elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation. Bone. 2007;40:1502\u201316.","journal-title":"Bone"},{"key":"1117_CR31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00007890-199702150-00009","volume":"63","author":"A Aroldi","year":"1997","unstructured":"Aroldi A, Tarantino A, Montagnino G, et al. Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. Transplant. 1997;63:380\u20136.","journal-title":"Transplant."},{"key":"1117_CR32","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcb.21411","volume":"103","author":"UK Singha","year":"2008","unstructured":"Singha UK, Jiang Y, Yu S, et al. Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem. 2008;103:434\u201346.","journal-title":"J Cell Biochem"},{"key":"1117_CR33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1749-6632.2002.tb04204.x","volume":"966","author":"E Canalis","year":"2002","unstructured":"Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann N Y Acad Sci. 2002;966:73\u201381.","journal-title":"Ann N Y Acad Sci"},{"key":"1117_CR34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ndt\/gfm816","volume":"23","author":"U Kunzendorf","year":"2008","unstructured":"Kunzendorf U, Kramer BK, Arns W, et al. Bone disease after renal transplantation. Nephrol Dial Transplant. 2008;23:450\u20138.","journal-title":"Nephrol Dial Transplant."},{"key":"1117_CR35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1210\/jcem-52-1-111","volume":"52","author":"TJ Hahn","year":"1981","unstructured":"Hahn TJ, Halstead LR, Baran DT, et al. Effects off short term glucocorticoid administration on interstitial calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab. 1981;52:111\u20135.","journal-title":"J Clin Endocrinol Metab."},{"key":"1117_CR36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1600-6143.2011.03872.x","volume":"12","author":"EL Nikkel","year":"2012","unstructured":"Nikkel EL, Mohan S, Zhang A, et al. Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. Am J Transplant. 2012;12:649\u201359.","journal-title":"Am J Transplant."},{"key":"1117_CR37","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.transproceed.2007.10.001","volume":"39","author":"G Lehman","year":"2007","unstructured":"Lehman G, Ott U, Stein G, et al. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant Proc. 2007;39:3153\u20138.","journal-title":"Transplant Proc."},{"key":"1117_CR38","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1681\/ASN.V1161093","volume":"11","author":"MC Monier-Faugere","year":"2000","unstructured":"Monier-Faugere MC, Mawad H, Qi Q, et al. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol. 2000;11:1093\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"1117_CR39","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2215\/CJN.01510506","volume":"6","author":"JR Weisinger","year":"2006","unstructured":"Weisinger JR, Carlini RG, Rojas E, et al. Bone disease after renal transplantation. Clin J Am Nephrol. 2006;6:1300\u201313.","journal-title":"Clin J Am Nephrol."},{"key":"1117_CR40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.5527\/wjn.v1.i5.127","volume":"6","author":"R Zhang","year":"2012","unstructured":"Zhang R, Chouhan KK, et al. Metabolic bone diseases in kidney transplant recipients. World J Nephrol. 2012;6:127\u201333.","journal-title":"World J Nephrol."},{"key":"1117_CR41","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1097\/01.TP.0000131990.13277.28","volume":"77","author":"VM Brandenburg","year":"2004","unstructured":"Brandenburg VM, Politt D, Ketteler M, et al. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplant. 2004;77:1566\u201371.","journal-title":"Transplant."},{"key":"1117_CR42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.ackd.2005.10.008","volume":"13","author":"AL Zisman","year":"2006","unstructured":"Zisman AL, Sprague SM, et al. Bone disease after kidney transplantation. Adv Chronic Kidney Dis. 2006;13:35\u201346.","journal-title":"Adv Chronic Kidney Dis."},{"key":"1117_CR43","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/j.1523-1755.2000.00394.x","volume":"58","author":"CO Stenman-Bareen","year":"2000","unstructured":"Stenman-Bareen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int. 2000;58:2200\u20135.","journal-title":"Kidney Int"},{"key":"1117_CR44","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1047-2797(01)00226-5","volume":"11","author":"KC Abbott","year":"2001","unstructured":"Abbott KC, Oglesby RJ, Hypolite IO, et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001;11:450\u20137.","journal-title":"Ann Epidemiol."},{"key":"1117_CR45","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1001\/jama.288.23.3014","volume":"18","author":"AM Ball","year":"2002","unstructured":"Ball AM, Gillen DL, Sherrard D, et al. Risk of hip fracture among dialysis and renal transplant recipients. Jam. 2002;18:3014\u20138.","journal-title":"Jam."},{"key":"1117_CR46","first-page":"69","volume":"51","author":"J Malyszko","year":"2006","unstructured":"Malyszko J, Malyszko JS, Pawlak K, et al. Tartrate-resistant acid phosphatase 5b and its correlations with other markers of bone metabolism in kidney transplant recipients and dialyzed patients. Adv Med Sci. 2006;51:69\u201372.","journal-title":"Adv Med Sci."},{"key":"1117_CR47","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5301\/jn.5000015","volume":"25","author":"AK Gupta","year":"2012","unstructured":"Gupta AK, Huang M, Prasad GV. Determinants of bone mineral density in stable kidney transplant recipients. J Nephrol. 2012;25:373\u201383.","journal-title":"J Nephrol."},{"key":"1117_CR48","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S0041-1345(03)00523-2","volume":"35","author":"J Malyszko","year":"2003","unstructured":"Malyszko J, Wlczynski S, Malyszko JS, et al. Correlations of new markers of bone formation and resorption in kidney transplant recipients. Transplant Proc. 2003;35:1351\u20134.","journal-title":"Transplant Proc."},{"key":"1117_CR49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.transproceed.2007.11.040","volume":"40","author":"G Bozkaya","year":"2008","unstructured":"Bozkaya G, Nart A, Uslu A, et al. Impact of calcineurin inhibitors on bone metabolism in primary kidney transplant patients. Transplant Proc. 2008;40:151\u20135.","journal-title":"Transplant Proc."},{"key":"1117_CR50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00007890-200107150-00017","volume":"15","author":"DN Cruz","year":"2001","unstructured":"Cruz DN, Wysolmerski JJ, Brickel HM, et al. Parameters of high bone-turnover predict bone loss in renal transplant patients: a longitudinal study. Transplant. 2001;15:83\u20138.","journal-title":"Transplant."},{"key":"1117_CR51","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2215\/CJN.00950110","volume":"5","author":"N Kanaan","year":"2010","unstructured":"Kanaan N, Claes K, Devogelaer JP, et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin J Am Soc Nephrol. 2010;5:1887\u201392.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1117_CR52","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000362492","volume":"39","author":"G Cianciolo","year":"2014","unstructured":"Cianciolo G, Capelli I, Angelini ML, et al. Importance of vascular calcification in kidney transplant recipients. Am J Nephrol. 2014;39:418\u201326.","journal-title":"Am J Nephrol"},{"key":"1117_CR53","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1523-1755.2005.00303.x","volume":"67","author":"D Hernandez","year":"2005","unstructured":"Hernandez D, Rufino M, Bartolomei S, et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int. 2005;67:2015\u201320.","journal-title":"Kidney Int"},{"key":"1117_CR54","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1093\/ndt\/gfq268","volume":"25","author":"PT Nguyen","year":"2010","unstructured":"Nguyen PT, Henrard S, Cohoe E, et al. Coronary artery calcification: a strong predictor of cardiovascular events in renal transplant recipients. Nephrol Dial Transplant. 2010;25:3773\u20138.","journal-title":"Nephrol Dial Transplant."},{"key":"1117_CR55","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1399-0012.2007.00690.x","volume":"21","author":"O Egbuna","year":"2007","unstructured":"Egbuna O, Taylor J, Buchinsky D, et al. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant. 2007;21:558\u201366.","journal-title":"Clin Transplant"},{"key":"1117_CR56","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1681\/ASN.2011121191","volume":"24","author":"R Shroff","year":"2013","unstructured":"Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol. 2013;24:179\u201389.","journal-title":"J Am Soc Nephrol"},{"key":"1117_CR57","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/ndt\/gfh303","volume":"19","author":"SM Moe","year":"2004","unstructured":"Moe SM, O\u2019Neill KD, Resleravasa M, et al. Natural history of vascular calcification in dialysis and transplantation patients. Nephrol Dial Transplant. 2004;19:2387\u2013793.","journal-title":"Nephrol Dial Transplant"},{"key":"1117_CR58","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2215\/CJN.03930808","volume":"4","author":"S Mazzaferro","year":"2009","unstructured":"Mazzaferro S, Pasquali M, Taggi F, et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol. 2009;4:685\u201390.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1117_CR59","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1093\/ndt\/gfn753","volume":"24","author":"SS DeLoach","year":"2009","unstructured":"DeLoach SS, Joffe MM, Mai X, et al. Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant. 2009;24:1314\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1117_CR60","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.ajkd.2011.07.019","volume":"59","author":"C Marechal","year":"2012","unstructured":"Marechal C, Coche E, Goffin E, et al. Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. Am J Kidney Dis. 2012;59:258\u201369.","journal-title":"Am J Kidney Dis"},{"key":"1117_CR61","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1681\/ASN.2010080894","volume":"22","author":"M Wolf","year":"2011","unstructured":"Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is risk factor for kidney transplant loss and mortality. J Am Soc Nephrol. 2011;22:956\u201366.","journal-title":"J Am Soc Nephrol"},{"key":"1117_CR62","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393\u2013408.","journal-title":"J Clin Invest."},{"key":"1117_CR63","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/emmm.201303716","volume":"6","author":"O Andrukhova","year":"2014","unstructured":"Andrukhova O, Slavic S, Smorodchenko A, et al. FGF23 regulates renal sodium handling and blood pressure. EMBO Mol Med. 2014;6:744\u201359.","journal-title":"EMBO Mol Med."},{"key":"1117_CR64","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s004410051353","volume":"297","author":"CG Bellows","year":"1999","unstructured":"Bellows CG, Reimers SM, Heersche JN, et al. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res. 1999;297:249\u201359.","journal-title":"Cell Tissue Res"},{"key":"1117_CR65","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","volume":"68","author":"J Cunningham","year":"2005","unstructured":"Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68:1793\u2013800.","journal-title":"Kidney Int"},{"key":"1117_CR66","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/TP.0b013e31817c13e1","volume":"86","author":"C Bergua","year":"2008","unstructured":"Bergua C, Torregrosa JV, Gutierrez-Dalmau A, et al. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplant. 2008;86:413\u20137.","journal-title":"Transplant"},{"key":"1117_CR67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00198-006-0238-3","volume":"18","author":"M Fleseriu","year":"2007","unstructured":"Fleseriu M, Licata AA. Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D. Osteoporos Int. 2007;18:363\u20138.","journal-title":"Osteoporos Int"},{"key":"1117_CR68","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1523-1755.2004.00432.x","volume":"65","author":"A Torres","year":"2004","unstructured":"Torres A, Garcia S, Gonzalez A, et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int. 2004;65:705\u201312.","journal-title":"Kidney Int"},{"key":"1117_CR69","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1097\/01.ASN.0000093255.56474.B4","volume":"14","author":"AE El-Agroudy","year":"2003","unstructured":"El-Agroudy AE, El-Husseini AA, El-Sayed M, et al. Preventing bone loss in renal transplant recipients with vitamin D. J Am Soc Nephrol. 2003;14:2975\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"1117_CR70","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1111\/j.1440-1797.2010.01234.x","volume":"15","author":"S Chadban","year":"2010","unstructured":"Chadban S, Chan M, Fry K, et al. The CARI guidelines. Nutritional management of hypophosphataemia in adult kidney transplant recipients. Nephrology (Carlton). 2010;15:S48\u201351.","journal-title":"Nephrology (Carlton)"},{"key":"1117_CR71","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0272-6386(99)70045-4","volume":"34","author":"PM Ambuhl","year":"1999","unstructured":"Ambuhl PM, Meier D, Wolf B, et al. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid\/base homeostasis. Am J Kidney Dis. 1999;34:875\u201383.","journal-title":"Am J Kidney Dis"},{"key":"1117_CR72","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1053\/j.ajkd.2010.11.024","volume":"57","author":"LV Riella","year":"2011","unstructured":"Riella LV, Rennke HG, Grafals M, et al. Hypophosphatemia in kidney transplant recipients: report of acute phosphate nephropathy as a complication of therapy. Am J Kidney Dis. 2011;57:641\u20135.","journal-title":"Am J Kidney Dis"},{"key":"1117_CR73","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/ndt\/13.10.2605","volume":"13","author":"F Caravaca","year":"1998","unstructured":"Caravaca F, Fernandez MA, Ruiz-Calero R, et al. Effects of oral phosphorus supplementation on mineral metabolism of renal transplant recipients. Nephrol Dial Transplant. 1998;13:2605\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"1117_CR74","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5414\/CNP63087","volume":"63","author":"M Balal","year":"2005","unstructured":"Balal M, Paydas S, Seyrek N, et al. Dipyridamole for renal phosphate leak in successfully renal transplanted hypophosphatemic patients. Clin Nephrol. 2005;63:87\u201391.","journal-title":"Clin Nephrol"},{"key":"1117_CR75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1053\/j.ajkd.2012.03.024","volume":"60","author":"AJ Felsenfeld","year":"2012","unstructured":"Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. Am J Kidney Dis. 2012;60:655\u201361.","journal-title":"Am J Kidney Dis"},{"key":"1117_CR76","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124:1587\u201397.","journal-title":"J Clin Invest."},{"key":"1117_CR77","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1093\/ndt\/gfm270","volume":"22","author":"AE Kruse","year":"2007","unstructured":"Kruse AE, Eisenberger U, Frey FJ, et al. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2007;22:2362\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"1117_CR78","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/ndt\/gfh924","volume":"20","author":"AE Kruse","year":"2005","unstructured":"Kruse AE, Eisenberger U, Frey FJ, et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1311\u20134.","journal-title":"Nephrol Dial Transplant"},{"key":"1117_CR79","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ndt\/gfl560","volume":"22","author":"AL Serra","year":"2007","unstructured":"Serra AL, Savoca R, Huber AR, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant. 2007;22:577\u201383.","journal-title":"Nephrol Dial Transplant"},{"key":"1117_CR80","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/ndt\/gfh925","volume":"20","author":"AL Serra","year":"2005","unstructured":"Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1315\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"1117_CR81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2215\/CJN.00500705","volume":"1","author":"TR Srinivas","year":"2006","unstructured":"Srinivas TR, Schold JD, Wormer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006;1:323\u20136.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1117_CR82","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1111\/j.1600-6143.2006.01475.x","volume":"6","author":"N Leca","year":"2006","unstructured":"Leca N, Laftavi M, Gundroo A, et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant. 2006;6:2391\u20135.","journal-title":"Am J Transplant"},{"key":"1117_CR83","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ndt\/gfl583","volume":"22","author":"A Schwarz","year":"2007","unstructured":"Schwarz A, Rustien G, Merkel S, et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant. 2007;22:584\u201391.","journal-title":"Nephrol Dial Transplant"},{"key":"1117_CR84","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MAJ.0b013e3181d8b6ff","volume":"339","author":"E Kandil","year":"2010","unstructured":"Kandil E, Florman S, Alabbas H, et al. Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci. 2010;339:420\u20134.","journal-title":"Am J Med Sci"},{"key":"1117_CR85","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","volume":"349","author":"DM Black","year":"2003","unstructured":"Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Eng J Med. 2003;349:1207\u201315.","journal-title":"N Eng J Med."},{"key":"1117_CR86","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1600-6143.2008.02327.x","volume":"8","author":"D Cejka","year":"2008","unstructured":"Cejka D, Benesch T, Krestan C, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant. 2008;8:1864\u201370.","journal-title":"Am J Transplant"},{"key":"1117_CR87","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756\u201365.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1117-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-015-1117-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1117-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T19:03:37Z","timestamp":1717873417000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-015-1117-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,2]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["1117"],"URL":"https:\/\/doi.org\/10.1007\/s10157-015-1117-z","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,2]]}}}